Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Prime potency
September 2019
SHARING OPTIONS:

OTTAWA, Ontario—July ended with news from Orion Biotechnology Canada Ltd. that OB-002, its lead compound, had demonstrated in an in-vitro potency assessment that it was more potent than other CCR5 antagonists being developed for HIV prevention and cancer indications. The compound was compared against maraviroc (Selzentry or Celsentri), a small-molecule CCR5 antagonist, and PRO-140 (leronlimab), a humanized antibody CCR5 antagonist. The drugs were evaluated in two models: an aequorin-based functional inhibition assay provided by Euroscreen Fast, and an HIV replication assay from ImQuest using CCR5-tropic HIV BaL strain with PBMC from 18 healthy individuals. In the first test, OB-002 potency (0.2 nM) was 13-fold higher than that of Maraviroc (2.6 nM) and 28-fold higher than that of PRO-140/Leronlimab (5.6 nM), and in the second, OB-002’s potency was consistently higher (8- to 80-fold) than that of maraviroc.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.